Perforin and lymphohistiocytic proliferative disorders

Area of Science:

• Immunology
• Genetics
• Molecular Biology

Background:

• Perforin is essential for the cytotoxic activity of natural killer (NK) cells and cytotoxic T lymphocytes (CTLs).
• Perforin deficiency in mice leads to impaired immune responses against viral and bacterial infections.
• Familial haemophagocytic lymphohistiocytosis (FHL) is a severe, life-threatening hyperinflammatory syndrome.

Purpose of the Study:

• To investigate the role of perforin in immune cytotoxicity and its link to familial haemophagocytic lymphohistiocytosis (FHL).
• To understand the clinical manifestations and genetic basis of FHL type 2.
• To explore potential diagnostic and therapeutic strategies for FHL.

Main Methods:

• Analysis of perforin-deficient mouse models to assess immune cell function and susceptibility to infections.
• Genetic analysis of patients with FHL to identify mutations in the perforin gene.
• Clinical evaluation of patients with FHL, including cytokine profiling and immune cell cytotoxicity assays.

Main Results:

• Perforin-deficient mice exhibit compromised NK and CTL cytotoxicity, leading to susceptibility to infections and development of haemophagocytic lymphohistiocytosis.
• Mutations in the perforin gene were identified as the cause of familial haemophagocytic lymphohistiocytosis type 2.
• FHL patients with perforin mutations show fever, hepatosplenomegaly, pancytopenia, elevated pro-inflammatory cytokines, and impaired NK/CTL function.

Conclusions:

• Perforin is critical for controlling infections and preventing FHL.
• Perforin gene mutations are a direct cause of FHL type 2, enabling prenatal diagnosis.
• While stem cell transplantation is curative, future gene therapy holds promise for treating FHL.